leadf
logo-loader
viewAntibe Therapeutics Inc

Antibe Therapeutics plans to file IND with regulator for lead drug otenaproxesul

The firm's lead drug is targeting the global need for a safer, non-addictive drug for chronic pain and inflammation

Antibe Therapeutics Inc -
"The company anticipates that the Phase 3 program for otenaproxesul will commence in late calendar Q1 or early calendar Q2 2021 and will take approximately 2 years to complete

Antibe Therapeutics Inc (CVE:ATE) (OTCQB:ATBPF) has revealed that it plans to file an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) for its lead drug otenaproxesul, formerly known as ATB-346, within the next six months, to allow for Phase 3 clinical trials in the US.

The news accompanied the Toronto-based pharma group's posting of its fiscal first-quarter results to end-June, 2020. Otenaproxesul is targeting the global need for a safer, non-addictive drug for chronic pain and inflammation.

READ: Antibe Therapeutics engages Stern IR to expand its investor relations program and broaden visibility within US capital markets

In successful Phase 2 trial results, released in June this year, both 250 mg and 200 mg doses of ATB-346 showed superiority to placebo in reducing pain with a high level of statistical significance.

"The company anticipates that the Phase 3 program for otenaproxesul will commence in late calendar Q1 or early calendar Q2 2021 and will take approximately 2 years to complete," the firm said in the results statement.

"Although the Phase 3 design is not finalized, it is expected to replicate the Phase 2B GI safety and Phase 2B dose-ranging, efficacy studies in a larger sample size with a longer treatment duration."

Antibe's main regulatory focus is to obtain FDA approval for otenaproxesul given that the USA is the largest pharmaceutical market worldwide. The firm has also engaged a European regulatory consulting agency to develop a strategy for EMA approval.

In keeping with a firm at this stage of development, Antibe's loss from operations for the three month period was C$4,918 against a loss of C$3,176 in the same period last year.

Revenue for the three months came in at C$1,229 compared to C$2,763 for the same period in 2019 due to the impact of the coronavirus (COVID-19) pandemic which caused dental clinics to close for a significant part of the quarter.

Contact the author at [email protected]

Quick facts: Antibe Therapeutics Inc

Price: 0.35 CAD

TSX-V:ATE
Market: TSX-V
Market Cap: $134.91 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Antibe Therapeutics Inc named herein, including the promotion by the Company of Antibe Therapeutics Inc in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Antibe Therapeutics releases data from company’s Phase II placebo-controlled...

Antibe Therapeutics (CVE: ATE) CEO Dan Legault joined Steve Darling from Proactive Vancouver with new results from the company’s analysis of primary and secondary data from ATB-346’s recent placebo-controlled efficacy trial. Legault shares the data with Proactive and he also maps out the...

on 08/12/2020

2 min read